IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that it is exploring a variety of strategic alternatives. The Company further stated that as part of the process the Board of Directors has formed a committee, which has retained Foros Securities LLC as its financial advisor. The Company has retained Deutsche Bank Securities Inc. as its financial advisor.
There can be no assurance that the exploration of strategic alternatives will result in a transaction. The Company does not expect to make further public comment regarding these matters while its exploration process continues.
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.3 billion in 2008 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.
Contacts:
IMS Health
Darcie Peck, 203-845-5237
Investor Relations
dpeck@imshealth.com
or
Gary
Gatyas, 610-834-4596
Communications
ggatyas@us.imshealth.com
